EYE.ASX: Record Revenues for FY25

Record Revenues for FY25

Stock	Nova EYE Medical Ltd (EYE.ASX)
Release Time	8 Jul 2025, 9:56 a.m.
Price Sensitive	Yes

This feature provides summaries of price-sensitive announcements for companies followed by users on InvestorPA. The summaries are generated by large language models so please interpret with care.

Nova Eye Medical Reports Record Revenues for FY25

Key Points

Record revenues of A$28.8m for FY25, up 21% from FY24
Six consecutive half-years of growth in the USA, with H2FY25 US sales up 25% on pcp
Q4FY25 sales of A$8.4m, the highest on record

Full Summary

Nova Eye Medical Limited (ASX: EYE) has reported a record sales result for the financial year ended 30 June 2025. Group revenue for FY25 reached A$28.8 million (US$18.4 million), up 21% (in constant currency) from FY24. The key drivers of this record performance include US sales of US$14.2 million, up 25% with the iTrack™ Advance device delivering six consecutive half-years of revenue growth. Second half FY25 sales reached A$15.7 million (US$10 million), up 46% on the prior corresponding period (in constant currency) and in line with guidance. Q4FY25 sales of A$8.4 million (US$5.4 million) were the highest on record. The record result underscores the continued adoption of iTrack™ Advance and growing global recognition of Nova Eye's technology. Nova Eye expects revenue growth to continue in FY26.

Guidance

Nova Eye expects revenue growth to continue in FY26.